| Basics |
United Therapeutics Corporation
United Therapeutics Corp is engaged in the healthcare sector. Its core offering includes pharmaceutical products to address unmet medical needs of patients.
|
| IPO Date: |
June 17, 1999 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$19.11B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.65 | 1.39%
|
| Avg Daily Range (30 D): |
$6.28 | 1.48%
|
| Avg Daily Range (90 D): |
$5.12 | 1.43%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.52M |
| Avg Daily Volume (30 D): |
.58M |
| Avg Daily Volume (90 D): |
.56M |
| Trade Size |
| Avg Trade Size (Sh.): |
88 |
| Avg Trade Size (Sh.) (30 D): |
32 |
| Avg Trade Size (Sh.) (90 D): |
34 |
| Institutional Trades |
| Total Inst.Trades: |
14,253 |
| Avg Inst. Trade: |
$4.94M |
| Avg Inst. Trade (30 D): |
$28.21M |
| Avg Inst. Trade (90 D): |
$25.81M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$9.41M |
| Avg Closing Trade (30 D): |
$49.58M |
| Avg Closing Trade (90 D): |
$38.48M |
| Avg Closing Volume: |
58.7K |
|
|
| News |
Oct 17, 2025 @ 2:00 PM
Artificial Lung Market to Grow at 10.84% CAGR, Hit...
Source: Towards Healthcare
|
Sep 11, 2025 @ 3:12 PM
3 High-Growth Stocks Poised to Extend Gains Into Y...
Source: Damian Nowiszewski
|
Aug 6, 2025 @ 2:26 PM
MannKind (MNKD) Q2 Revenue Rises 6%
Source: Jesterai
|
Jul 28, 2025 @ 6:48 PM
ROSEN, A LEADING LAW FIRM, Encourages 3D Systems C...
Source: Rosen Law Firm
|
Jul 25, 2025 @ 1:20 AM
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages 3D Sy...
Source: Rosen Law Firm
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$27.68
|
$6.86
|
$7.18
|
|
Diluted EPS
|
$25.62
|
$6.41
|
$6.63
|
|
Revenue
|
$ 3.08B
|
$ 798.6M
|
$ 794.4M
|
|
Gross Profit
|
$ 2.74B
|
$ 711M
|
$ 701.9M
|
|
Net Income / Loss
|
$ 1.24B
|
$ 309.5M
|
$ 322.2M
|
|
Operating Income / Loss
|
$ 1.45B
|
$ 364.5M
|
$ 382.8M
|
|
Cost of Revenue
|
$ 339.1M
|
$ 87.6M
|
$ 92.5M
|
|
Net Cash Flow
|
$ 237.4M
|
$ -306.8M
|
$ 202.7M
|
|
PE Ratio
|
0.00
|
|
|
|
|
|
